ERBB2 and breast carcinoma: In clinical research, PYR has demonstrated effective improvements in disease‐free and overall survival in patients with HER2‐positive breast cancer.[10] Nonetheless, the free form of this small‐molecule chemotherapeutic agent has limitations such as poor bioavailability and short action period, and is associated with systemic and organ toxicity.